BMY Stock Recent News

BMY's double-beat FQ2'25 performance and raised FY2025 guidance have been met with much skepticism, as observed in the steep pullback post earnings. This is despite the Growth Portfolio comprising over 50% of its overall revenues, with further expansion likely thanks to its intensified R&D, partnerships, and M&A efforts. BMY's discounted valuations present a deep-value buying opportunity, with patient investors well rewarded with rich dividend yields, pending growth acceleration.

Bristol-Myers Squibb Company beat Q2 2025 revenue expectations and raised full-year guidance, but EPS guidance was lowered and shares remain under pressure. The company's growth portfolio is expanding, but heavy reliance on Eliquis and Opdivo, both facing patent expiries, clouds the outlook. Key upcoming data catalysts and a new CMO offer hope, yet recent drug launches and acquisitions have underperformed expectations.

Bristol-Myers Squibb's Q2 2025 results were a mixed bag, with revenues showing signs of recovery while earnings saw a pullback. A reduction in earnings guidance on IPRD charges was another disappointment, though early signs of the performance of acquired treatment Cobenfy are positive. Underwhelming earnings since last year, along with revenues that are still coming back in form could explain the loss of price momentum for BMY despite otherwise healthy stock metrics.

Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.

CNBC's Joe Kernen reports on the latest news.

Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2025 Earnings Conference Call July 31, 2025 8:00 AM ET Company Participants Adam Lenkowsky - Executive VP & Chief Commercialization Officer Christopher S. Boerner - CEO & Chairman Chuck Triano - Corporate Participant David V.

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.

BMY's Q2 EPS and revenues beat estimates, powered by strong Growth portfolio sales and a lesser than expected decline in Legacy portfolio sales.